pharmaphorum

OCTOBER 14, 2022

The project started on 1 October and is scheduled to complete in September 2026. The post Janssen leads effort to cut waste in digital health devices appeared first on. Photo by Possessed Photography on Unsplash.

Leads 124

Leads Electronics Ethics Healthcare 124

European Pharmaceutical Review

DECEMBER 22, 2023

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. This represents a 53 percent premium on Karuna’s closing stock price on 21 December 2023.

Food and Drug Administration 98

Food and Drug Administration Side effects Safety Food 98

Pharmaceutical Technology

JUNE 2, 2023

More significantly, the revised contract secures about 70 million vaccine doses every year from 2023 to 2026 for member states, leaving little space in the market for competitors. This deal, therefore, serves as a threat to other vaccine developers with authorisations for distribution in the EU, including Moderna, Novavax, and Sanofi.

Leads 52

Leads Safety Distribution Marketing 52

European Pharmaceutical Review

MARCH 9, 2023

There are emerging trends in oncology, with new chemical entities (NCEs) and antibody-drug conjugates (ADC) leading to increased demand for HPAPI manufacturing capabilities. It’s a collaborative approach from safety, engineering, toxicology, and operations to have the most robust potent compound safety.

Safety 98

Safety Pharmacology Training Manufacturing 98

European Pharmaceutical Review

FEBRUARY 12, 2024

Liam Dunne, MSD Biotech Site Lead, explains that the site operates at the forefront of science and technology with 15,000L-scale, repeatable, robust manufacturing processes to produce highly sensitive monoclonal antibodies (mAbs). The downstream process ensures cell removal, virus safety, and impurity removal. How does it do this?

Manufacturing 98

Manufacturing Medicine Leads Patients 98

Pharmaceutical Technology

JULY 26, 2022

Following the merger, NewAmsterdam Pharma CEO Dr Michael Davidson will lead the newly formed holding company, which is expected to be named NewAmsterdam Pharma Company. This pro forma cash balance of nearly $470m is anticipated to offer a cash runway for the merged company through 2026.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

pharmaphorum

JULY 26, 2022

Merck’s exit came after other companies including Pfizer, Eli Lilly and Roche all scrapped CETP development programmes following safety or efficacy issues. BROADWAY and BOOKLYN will generate data in 2024, with PREVAIL set to read to in 2026, and if the results are positive will be followed by filings in the US, Europe, China and Japan.

Side effects 52

Side effects Safety Pharma Patients 52